These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7593908)

  • 1. Pharmacokinetics of continuous renal replacement therapy.
    Schetz M; Ferdinande P; Van den Berghe G; Verwaest C; Lauwers P
    Intensive Care Med; 1995 Jul; 21(7):612-20. PubMed ID: 7593908
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage.
    Böhler J; Donauer J; Keller F
    Kidney Int Suppl; 1999 Nov; (72):S24-8. PubMed ID: 10560800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug removal in continuous haemofiltration and haemodialysis.
    Davies JG; Kingswood JC; Sharpstone P; Street MK
    Br J Hosp Med; 1995 Nov 15-Dec 12; 54(10):524-8. PubMed ID: 8574497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug administration in critically ill patients with acute renal failure.
    Kroh UF
    New Horiz; 1995 Nov; 3(4):748-59. PubMed ID: 8574606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous arteriovenous hemofiltration improvement by adding diffusion and adsorption.
    Marangoni R; Civardi F; Savino R; Masi F
    Contrib Nephrol; 1991; 93():156-61. PubMed ID: 1802570
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients.
    Bugge JF
    Acta Anaesthesiol Scand; 2001 Sep; 45(8):929-34. PubMed ID: 11576041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug removal during continuous hemofiltration or hemodialysis.
    Golper TA
    Contrib Nephrol; 1991; 93():110-6. PubMed ID: 1802557
    [No Abstract]   [Full Text] [Related]  

  • 8. What are the important drug use errors in dialysis patients? Pharmacokinetic and pharmacodynamic principles.
    Dager WE
    Semin Dial; 2010; 23(5):466-9. PubMed ID: 21069914
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of continuous renal replacement therapy on drug therapy.
    Susla GM
    Clin Pharmacol Ther; 2009 Nov; 86(5):562-5. PubMed ID: 19727069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics of vancomycin in continuous veno-venous hemofiltration].
    Gu Q; Zhu ZH; Ge M; Ge WH
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Feb; 15(2):114-6. PubMed ID: 12857476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High efficiency hemodialysis.
    Keshaviah P; Collins A
    Contrib Nephrol; 1989; 69():109-19; discussion 162-7. PubMed ID: 2661135
    [No Abstract]   [Full Text] [Related]  

  • 12. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure.
    Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Picetti E; Sagripanti S; Manini P; Andreoli R; Cabassi A
    Crit Care Med; 2004 Dec; 32(12):2437-42. PubMed ID: 15599148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapies.
    Vilay AM; Shah KH; Churchwell MD; Patel JH; DePestel DD; Mueller BA
    Blood Purif; 2010; 30(1):37-43. PubMed ID: 20588011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of antitubercular agents for disseminated Mycobacterium tuberculosis during intermittent haemodialysis and continuous venovenous haemofiltration.
    Sin JH; Elshaboury RH; Hurtado RM; Letourneau AR; Gandhi RG
    J Clin Pharm Ther; 2018 Apr; 43(2):291-295. PubMed ID: 28895161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal replacement therapy III: IHD, CRRT, SLED.
    O'Reilly P; Tolwani A
    Crit Care Clin; 2005 Apr; 21(2):367-78. PubMed ID: 15781169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentobarbital Removal During Continuous Venovenous Hemofiltration: Case Report and Review of the Literature.
    Hensler DM; McConnell DP; Levasseur-Franklin KE; Greathouse KM
    J Pharm Pract; 2018 Dec; 31(6):682-686. PubMed ID: 29162023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal replacement II: dialysis dose.
    Ricci Z; Ronco C
    Crit Care Clin; 2005 Apr; 21(2):357-66. PubMed ID: 15781168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.
    Veltri MA; Neu AM; Fivush BA; Parekh RS; Furth SL
    Paediatr Drugs; 2004; 6(1):45-65. PubMed ID: 14969569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citrate-based replacement solutions with continuous venovenous hemofiltration: not as simple as it sounds.
    Tolwani A; Wille KM
    Am J Kidney Dis; 2006 Jun; 47(6):1086; author reply 1086-7. PubMed ID: 16731311
    [No Abstract]   [Full Text] [Related]  

  • 20. The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies.
    Hernandez SH; Howland M; Schiano TD; Hoffman RS
    Clin Toxicol (Phila); 2015; 53(10):941-9. PubMed ID: 26484583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.